Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 13/20 | 0.73 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17959017 | 0.91 | HDAC6 (0.60) | HDAC6HDAC8KDM4EHTTHDAC1 | |
| SCHEMBL17959016 | 0.91 | HDAC6 (0.73) | HDAC6KEAP1HDAC8NPC1RAB9A | |
| SCHEMBL17960144 | 0.91 | HDAC6 (0.68) | HDAC6KEAP1HDAC8NPC1RAB9A | |
| SCHEMBL17960525 | 0.90 | HDAC6 (0.66) | HDAC6KEAP1HDAC8NPC1RAB9A | |
| SCHEMBL17960341 | 0.88 | HDAC6 (0.63) | HDAC6KEAP1HDAC8NPC1RAB9A | |
| SCHEMBL17959065 | 0.86 | HDAC6 (0.69) | HDAC6KEAP1HDAC8NPC1RAB9A | |
| SCHEMBL20967842 | 0.85 | HDAC6 (0.61) | HDAC6KEAP1NPC1RAB9AKDM4E | |
| SCHEMBL17960362 | 0.85 | HDAC6 (0.59) | HDAC6HDAC8NPC1RAB9AHDAC1 | |
| SCHEMBL17959002 | 0.83 | HDAC6 (0.60) | HDAC6HDAC8NPC1RAB9AKDM4E | |
| SCHEMBL17960195 | 0.82 | HDAC6 (0.56) | HDAC6HDAC8KDM4EHTTHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10870645-B2 | Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2020-12-22 | — | — | US | claimed |
| US-20190345149-A1 | BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | Valo Health, LLC | 2019-11-14 | — | — | US | claimed |
| WO-2016126726-A1 | BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC6 INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2016-08-11 | — | — | WO | claimed |
| US-20160221997-A1 | BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | Valo Health, LLC | 2016-08-04 | — | — | US | claimed |
| US-12304904-B2 | Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors | VALO HEALTH, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-20230357216-A1 | BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | Valo Health, LLC | 2023-11-09 | — | — | US | disclosed |
| US-11702412-B2 | Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors | VALO HEALTH, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20210206755-A1 | BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | VALO HEALTH, INC. | 2021-07-08 | — | — | US | disclosed |
| US-10870645-B2 | Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2020-12-22 | — | — | US | disclosed |
| US-20190345149-A1 | BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | Valo Health, LLC | 2019-11-14 | — | — | US | disclosed |
| US-10407418-B2 | Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| US-20190092762-A1 | BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2019-03-28 | — | — | US | disclosed |
| US-10183934-B2 | Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-01-22 | — | — | US | disclosed |
| WO-2016126726-A1 | BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC6 INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2016-08-11 | — | — | WO | disclosed |
| US-20160221997-A1 | BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | Valo Health, LLC | 2016-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357216-A1 | BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | HDAC1, HDAC2, HDAC4 | HDAC6 7/4885KEAP1 1169/4885HDAC8 9/4885 |
| US-10870645-B2 | Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors | HDAC1, HDAC2, HDAC4 | HDAC6 7/4885KEAP1 1169/4885HDAC8 9/4885 |
| US-10407418-B2 | Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors | HDAC1, HDAC2, HDAC4 | HDAC6 7/4885KEAP1 1169/4885HDAC8 9/4885 |
| US-20160221997-A1 | BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | HDAC1, HDAC2, HDAC4 | HDAC6 7/4885KEAP1 1169/4885HDAC8 9/4885 |
| US-10183934-B2 | Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors | HDAC1, HDAC2, HDAC4 | HDAC6 7/4885KEAP1 1169/4885HDAC8 9/4885 |
| US-12304904-B2 | Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors | HDAC1, HDAC2, HDAC4 | HDAC6 7/4885KEAP1 1169/4885HDAC8 9/4885 |
| US-20190092762-A1 | BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | HDAC1, HDAC2, HDAC4 | HDAC6 7/4885KEAP1 1169/4885HDAC8 9/4885 |
| US-11702412-B2 | Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors | HDAC1, HDAC2, HDAC4 | HDAC6 7/4885KEAP1 1169/4885HDAC8 9/4885 |
| US-20190345149-A1 | BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | HDAC1, HDAC2, HDAC4 | HDAC6 7/4885KEAP1 1169/4885HDAC8 9/4885 |
| US-20210206755-A1 | BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | HDAC1, HDAC2, HDAC4 | HDAC6 7/4885KEAP1 1169/4885HDAC8 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.